MIT researchers released BoltzGen, an update to their Boltz series that moves beyond structure prediction toward generalizable therapeutic design across modalities including nanobodies, mini‑binders and peptides. The model is available under an MIT license intended to allow commercial use and internal industry application. The preprint reports broad collaborator validation, with early wet‑lab results showing nanomolar affinities across diverse targets. The team highlighted BoltzGen’s potential to propose designs for previously undruggable targets and stressed ongoing experimental validation with academic and industry partners. Authors and academic partners framed the release as a tool to democratize therapeutic design while collaborators advance real‑world validation.